FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220654002> ?p ?o ?g. }

• W4220654002 endingPage "1377" @default.
• W4220654002 startingPage "1377" @default.
• W4220654002 abstract "Background: Treatment with the TLR-3 agonist rintatolimod may improve pancreatic cancer patients’ survival via immunomodulation, but the effect is unproven. Methods: In this single-center named patient program, patients with locally advanced pancreatic cancer (LAPC) or metastatic disease were treated with rintatolimod (six weeks total, twice per week, with a maximum of 400 mg per infusion). The primary endpoints were the systemic immune-inflammation index (SIII), the neutrophil to lymphocyte ratio (NLR), and the absolute counts of 18 different populations of circulating immune cells as measured by flow cytometry. Secondary endpoints were progression-free survival (PFS) and overall survival (OS). Subgroup analyses were performed in long-term survivors (>1-year overall survival after starting rintatolimod) and compared to short-term survivors (≤1 year). Results: Between January 2017 and February 2019, twenty-seven patients with stable LAPC or metastatic disease were pre-treated with FOLFIRINOX and treated with rintatolimod. Rintatolimod treatment was well-tolerated. The SIII and NLR values were significantly lower in the 11 long-term survivors, versus 16 short-term survivors. The numbers of B-cells were significantly increased in long-term survivors. Numbers of T cells and myeloid cells were not significantly increased after treatment with rintatolimod. Median PFS was 13 months with rintatolimod, versus 8.6 months in a subset of matched controls (n = 27, hazard ratio = 0.52, 95% CI = 0.28−0.90, p = 0.007). The median OS was 19 months with rintatolimod, versus 12.5 months in the matched control (hazard ratio = 0.51, 95% CI = 0.28−0.90, p = 0.016). Conclusions: Treatment with rintatolimod showed a favorable effect on the numbers of peripheral B cells in patients with pancreatic cancer and improved survival in pancreatic cancer, but additional evidence is required." @default.
• W4220654002 created "2022-04-03" @default.
• W4220654002 creator A5004273348 @default.
• W4220654002 creator A5006641161 @default.
• W4220654002 creator A5006707635 @default.
• W4220654002 creator A5014512905 @default.
• W4220654002 creator A5016295167 @default.
• W4220654002 creator A5022214407 @default.
• W4220654002 creator A5051575377 @default.
• W4220654002 creator A5053003095 @default.
• W4220654002 creator A5071589826 @default.
• W4220654002 date "2022-03-08" @default.
• W4220654002 modified "2023-09-26" @default.
• W4220654002 title "Rintatolimod (Ampligen®) Enhances Numbers of Peripheral B Cells and Is Associated with Longer Survival in Patients with Locally Advanced and Metastasized Pancreatic Cancer Pre-Treated with FOLFIRINOX: A Single-Center Named Patient Program" @default.
• W4220654002 cites W1521708716 @default.
• W4220654002 cites W1525615307 @default.
• W4220654002 cites W1968955362 @default.
• W4220654002 cites W1971045102 @default.
• W4220654002 cites W1998143989 @default.
• W4220654002 cites W1998252979 @default.
• W4220654002 cites W2016920052 @default.
• W4220654002 cites W2017271198 @default.
• W4220654002 cites W2032655351 @default.
• W4220654002 cites W2033023829 @default.
• W4220654002 cites W2051414417 @default.
• W4220654002 cites W2054265941 @default.
• W4220654002 cites W2070793039 @default.
• W4220654002 cites W2087747665 @default.
• W4220654002 cites W2088091610 @default.
• W4220654002 cites W2128142540 @default.
• W4220654002 cites W2151253787 @default.
• W4220654002 cites W2152842365 @default.
• W4220654002 cites W2235361305 @default.
• W4220654002 cites W2258061020 @default.
• W4220654002 cites W2345822778 @default.
• W4220654002 cites W2467479187 @default.
• W4220654002 cites W2520500352 @default.
• W4220654002 cites W2752977230 @default.
• W4220654002 cites W2782689871 @default.
• W4220654002 cites W2784112501 @default.
• W4220654002 cites W2793595591 @default.
• W4220654002 cites W2800389517 @default.
• W4220654002 cites W2949162809 @default.
• W4220654002 cites W3010087932 @default.
• W4220654002 cites W3023906975 @default.
• W4220654002 cites W3023998523 @default.
• W4220654002 cites W3046354124 @default.
• W4220654002 cites W3090259666 @default.
• W4220654002 cites W3092885209 @default.
• W4220654002 cites W3095442910 @default.
• W4220654002 cites W3096886921 @default.
• W4220654002 cites W3119474879 @default.
• W4220654002 cites W3174722064 @default.
• W4220654002 cites W4211253487 @default.
• W4220654002 doi "https://doi.org/10.3390/cancers14061377" @default.
• W4220654002 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35326528" @default.
• W4220654002 hasPublicationYear "2022" @default.
• W4220654002 type Work @default.
• W4220654002 citedByCount "2" @default.
• W4220654002 countsByYear W42206540022023 @default.
• W4220654002 crossrefType "journal-article" @default.
• W4220654002 hasAuthorship W4220654002A5004273348 @default.
• W4220654002 hasAuthorship W4220654002A5006641161 @default.
• W4220654002 hasAuthorship W4220654002A5006707635 @default.
• W4220654002 hasAuthorship W4220654002A5014512905 @default.
• W4220654002 hasAuthorship W4220654002A5016295167 @default.
• W4220654002 hasAuthorship W4220654002A5022214407 @default.
• W4220654002 hasAuthorship W4220654002A5051575377 @default.
• W4220654002 hasAuthorship W4220654002A5053003095 @default.
• W4220654002 hasAuthorship W4220654002A5071589826 @default.
• W4220654002 hasBestOaLocation W42206540021 @default.
• W4220654002 hasConcept C121608353 @default.
• W4220654002 hasConcept C126322002 @default.
• W4220654002 hasConcept C143998085 @default.
• W4220654002 hasConcept C168563851 @default.
• W4220654002 hasConcept C203014093 @default.
• W4220654002 hasConcept C203092338 @default.
• W4220654002 hasConcept C207103383 @default.
• W4220654002 hasConcept C2777148230 @default.
• W4220654002 hasConcept C2777761686 @default.
• W4220654002 hasConcept C2778963024 @default.
• W4220654002 hasConcept C2780073493 @default.
• W4220654002 hasConcept C2780210213 @default.
• W4220654002 hasConcept C2780962732 @default.
• W4220654002 hasConcept C44249647 @default.
• W4220654002 hasConcept C526805850 @default.
• W4220654002 hasConcept C71924100 @default.
• W4220654002 hasConcept C8891405 @default.
• W4220654002 hasConcept C90924648 @default.
• W4220654002 hasConceptScore W4220654002C121608353 @default.
• W4220654002 hasConceptScore W4220654002C126322002 @default.
• W4220654002 hasConceptScore W4220654002C143998085 @default.
• W4220654002 hasConceptScore W4220654002C168563851 @default.
• W4220654002 hasConceptScore W4220654002C203014093 @default.
• W4220654002 hasConceptScore W4220654002C203092338 @default.
• W4220654002 hasConceptScore W4220654002C207103383 @default.
• W4220654002 hasConceptScore W4220654002C2777148230 @default.
• W4220654002 hasConceptScore W4220654002C2777761686 @default.

• next